Case study

From paper to practise – a case study in PUPSIT

The context

Committing to a pre-use post-sterilization integrity testing (PUPSIT) strategy is a significant undertaking because, while some regulatory bodies recommend it, it may compromise downstream sterility and its implementation is associated with increased process complexity. This is why PUPSIT continues to generate considerable debate in the biopharmaceutical industry. To help support informed decision-making in this area, the BioPhorum/PDA Sterilizing Filtration Quality Risk Management Consortium has produced a series of articles. One of these is a paper titled Strategy roadmap for the implementation of a risk-based approach to pre-use post-sterilization integrity testing (PUPSIT). This allows companies to use scientific data and risk-based approaches to make and defend decisions related to PUPSIT.
Roche is one of the companies that has used the document to develop an internal position paper on PUPSIT and create its own risk-based approach, which is based on the BioPhorum/PDA PUPSIT strategy.

The story

“We’re a large company with different manufacturing sites and multiple filling lines in each site,” said Marc Steffens, Global Project Manager at Roche. “So it’s always been a challenge to establish harmonized processes, approaches, and strategies across our network. The same has been true for PUPSIT. The internal PUPSIT landscape is very diverse, and we have some sites and filling lines that do PUPSIT, while others don’t. As a result, we didn’t have a fully consistent strategy for how to assess the need for PUPSIT based on scientific considerations.”

Steffens added that the standardization of processes and the harmonization across the networks have always been key topics for Roche, so the BioPhorum/PDA consortium work is highly valued. “Based on this work, we have been able to establish guidelines to ensure that each site and each filling line is assessing this topic in the same manner. This will also improve our position when discussing our strategy with regulators or inspectors. For example, where we received previous observations, while not explicitly related to PUPSIT, inspectors noticed that one site does it one way while another does it differently. This leads to another critical step for us, towards a consistent approach.”

Steffens said that BioPhorum’s paper added value because Roche was looking for a more consistent strategy for PUPSIT as each site had previously created individual assessments. 

These were not necessarily done in the same way and with the same focus. Most of the assessments focused on the risk of using a flawed, non-integral filter, but disregarded the product properties that could lead to clogging of a flawed membrane. But it’s the combination of these two issues that results in a flaw-masking risk, i.e., the only scientific trigger for PUPSIT.

Marc Steffens, Global Project Manager at Roche

The outcomes

Steffens added that a significant change was that Roche was now applying an industry approach to PUPSIT. “This is important as it means we’re speaking as an industry, which helps us to, for example, defend our position in front of regulators.” He also commented that, previously, Roche had already used risk-based assessments but that the BioPhorum work had helped the team incorporate additional risk factors such as the flaw masking risk. Kewei Yang, Principal Scientist/Pharmaceutical Project Leader at Roche, explained this industry approach also helped the global roll-out of the new guidance. “We translated the BioPhorum work into our first internal guidance on this topic, for which we got endorsement and agreement from all our different manufacturing sites. It meant we now have an agreed global internal strategy for interpreting the EMA’s requirements on PUPSIT. Different sites used to interpret the regulatory requirements and prepared their risk assessment in their own way, so the outcomes from each site were different. Now we are aligning our strategy across sites and countries.” Roche has not only started to implement the BioPhorum approach but has already taken the next step. “After creating our internal guidance in 2021,” said Steffens, “we’re now in discussions with the different sites on setting up a risk assessment template to provide end-users with concrete and specific guidance on how to assess the flaw-masking risk. “One outcome of the end-user assessments could be that PUPSIT doesn’t make sense from a scientific perspective and hence may justify the removal of that step. But we’re just at the beginning of the process and the implementation will continue over the next few years. We haven’t had any inspection or audits in the last few months where PUPSIT was challenged, so we haven’t yet had any feedback on the strategy we’re now applying.”

Lessons learned

Steffens said that communication and dialogue, especially with health authorities, were important. “Once the BioPhorum/PDA consortium started these discussions, it soon became clear that we all have the same problems and questions, and that each company is struggling with PUPSIT. So, it’s also essential to be transparent on what we’re doing and what our strategy looks like. As PUPSIT is a compliance-related topic, discussions should include not only technical subject matter experts but also those from the quality department.” Yang explained he had learned a lot from the discussions in the BioPhorum team and that the publication would be valuable to the whole pharmaceutical industry. “It has been a great experience to join the BioPhorum discussions with experts from the other companies. These help us challenge our opinions and share our knowledge and know-how. A lesson learned is the importance of communicating with the different stakeholders; for example, our manufacturing colleagues from the different drug product sites, QA teams, and global functions. Communication is essential as this helped us get an endorsement from the different sides and ultimately establish a company guidance on this topic.”

Cell & Gene Therapy

Maximizing the impact of the many advanced therapies under development requires that the industry comes together to improve understanding of how to develop, control and manufacture these life changing therapies.

We connect strategic thinkers in drug development and contract manufacturing organizations with the aim of ensuring harmonization and alignment around issues such as potency assays, phase-appropriate guidance for critical quality attributes, operator safety, regulatory guidelines, and C&GT-specific validation issues, as well as working toward resolving the current challenges to commercializing C&GT products. Discover more and learn about the outputs here.

Development Group

The ever-increasing need to reduce product development lead times and the opportunities to exploit innovative technologies in development are two key industry themes that remain at the forefront of our work. The Phorum successfully connects process development organizations and provides a space where subject matter experts can work on issues such as quality by design and process characterization, cell line technologies, and molecule selection. Read some of the outputs and discover how you could benefit by getting involved.

Drug Substance

Accelerating improvement, exploiting opportunities offered by innovation, and identifying best practice approaches across all aspects of the manufacturing process – these are the essential objectives

Data and digital capabilities are at the core of many of these industry challenges. Work in BioPhorum Drug Substance is informed by BioPhorum Technology Strategy, which has summarized our industry’s market drivers and trends. Capacity, flexibility, sustainability and pace all feature as requirements to succeed in a rapidly changing environment.

Find out more about what our members are currently discussing and learn about some of the successful implementations of our output.

Fill Finish

Quality and demonstrating compliance are two priorities of BioPhorum Fill Finish. Representatives of the world’s top sterile filling operations come together to develop solutions to some of the most intractable technical and regulatory challenges.To address these challenges in drug product aseptic filling (‘fill’) and secondary packaging (‘finish’) operations, our community of industry experts is working relentlessly to continually improve the pharmaceutical quality system (PQS). Together they continue to strive towards developing and implementing safe, predictable, lean, and agile processes in drug product operations. Find out more about the Phorum output here. 

Information Technology

IT and digital advances are crucial in responding to the pharmaceutical industry’s challenges around speed, cost, quality, flexibility, and sustainability. Unlocking and realizing the value in the industry’s IT opportunities is the core mission of the IT Phorum. 

The digital manufacturing facility of the future needs to consider technology advances alongside organizational perspectives while maintaining foundational security requirements. All elements must be considered in the long term to deliver systemic change toward the digital factory vision. Our members collaborate in a format that stimulates and supports industry innovation and implementation. 


BioPhorum Regulatory CMC is affording professionals the opportunity to shape their own collaboration program focused on challenges and opportunities across strategy, science, operations, submissions and compliance. Following a discovery program of work with Heads of Regulatory CMC, in which we identified some key topics of collaboration, we are giving you the opportunity to participate and help us to shape the final collaboration program. This will focus on, filing and review, interactions with Health Authorities, and harmonization. Our mission is not just to discuss, but to deliver applicable outputs and publications that will have an impact – learn more about how you can get involved.

Supply Chain to Patient

The pharmaceutical outbound supply chain was built on a blockbuster model and doesn’t fit the needs of the changing pipeline and new modalities currently being developed. The geopolitical challenges of recent years have shown that the outbound supply chain needs to evolve to become more agile, and resilient, and address a more expectant end-user bying on patient-centricity. Industry collaboration can accelerate improvements and transform performance in a way not possible when working independently. This Phorum is founded on the belief that learning from each other and challenging current thinking to re-imagine the supply chain can reduce costs and increase efficiency.

Supply Partner

BioPhorum SP members want the inbound supply chain for the biomanufacturing industry to be recognized as one of the best-understood and managed global supply chains. They intend to be not only a trusted advisory group but also the engine that drives change for the industry. Working together, we aim to achieve supply chain transformation that provides:

  • an enhanced robustness and resilience
  • accelerated capability and capacity to effect technology adoption
  • reduced cost of quality, and
  • industry-wide alignment on operational implementation

There’s an extensive list of Phorum successes and tangible benefits that have been delivered to define industry best practise.


The BioPhorum Sustainability program is jointly designed, governed, and delivered by a membership drawn from licence holders, contract manufacturers, major suppliers and niche suppliers. This dynamic partnership means that we can quickly focus on the areas that have the greatest industry impact, and we can leverage learning from each other and other sectors – the chemical industry and the built environment for example.

BioPhorum’s unique ability to build a strong coalition for change for an entire industry is now being applied to the greatest challenge of our generation. Driven by evident industry needs, Phorum members are working to develop agreed industry benchmarks, establish the ROI of sustainability investments and to increase the efficacy of implementation of members’ sustainability strategies.

Technology Strategy

With a mission to define strategies to accelerate technology transformation and support the adoption of innovative technologies, BioPhorum Technology Strategy evolved from BioPhorum Technology Roadmapping, strives to realize the technology roadmap vision 2.0.

This is being achieved through a multi-stakeholder team of member companies with collective capability and influence who are committed to driving forth industry goals associated with: Speed to market, Quality, Value, Agility and On-Demand Supply and Sustainability.

Building on industry feedback to standardize plasmid release specifications

Plasmids release specifications are critical to the manufacture of many cell and gene therapy (CGT) products, but current regulatory... read more

How to predict, optimize and analyze high-concentration biologic therapeutic formulations

Developing high-dose biologic drugs for subcutaneous injection often requires high-concentration formulations. It also needs to optimize... read more

A media fingerprinting toolbox that comes with a host of benefits

Cell culture media raw materials can contain many chemical substances, each with its own properties. While simple substances can be... read more

Why 100% visual inspection does not mean 100% defect detection

There is a common misunderstanding that 100% visual inspection (VI) of biopharmaceutical products should mean 100% detection of defects.... read more

How to bridge the data integration gap between sponsors and contract organizations

Bringing BioPhorum’s unique perspective to continuous manufacturing in biologics

Continuous manufacturing (CM) has been a goal for the pharmaceutical industry for several years. While small molecule drug substances and... read more

Supply Chain to Patient has launched!

Have your outbound supply chain costs increased? Do you want to leverage data and digital technologies more effectively to reduce... read more

Electronic data exchange – the foundation for an efficient, resilient inbound supply chain

The COVID-19 pandemic, geopolitical unrest, and military action across the world have fundamentally disrupted the assumption and practice... read more

How are you improving your environmental sustainability performance?

Climate change and global warming resulting from greenhouse gas emissions are widely recognized as the biggest threats to global health.... read more

Adding value for analytical instrument partners

Analytical instrument vendors have been integral to developing and publishing our technology roadmaps and developing product... read more

Introducing MediPhorum

The medical technology (MedTech) industry is a critical and complex sector. As highlighted during the Covid-19 pandemic, the MedTech industry provides a wide array of products and technologies that are vital to the safe and effective provision of care to many. Also, as seen over recent years, there is often the requirement for flexibility in supply, rapid development, and the introduction of new products to keep pace with global public health demands.

Advanced Wound Care and Wound Management

Advanced wound care (AWC) is the medical treatment for wounds that have not healed properly using conventional wound care products such as gauze, bandages, plasters, and wadding.

AWC involves treating chronic or complex wounds using products that are not as easily obtained over the counter. AWC can be divided into three main categories: wound healing, infection prevention, and restoration.

Drug Delivery

Drug delivery products are therapeutic and diagnostic products combining drugs, devices, and/or biological products, which enable safer and more efficient treatment due to careful and precise drug targeting, local administration, and tailored treatment.

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more

Introducing the new MediPhorum

MediPhorum by BioPhorum has been launched to bring together senior business leaders and subject matter experts across multiple MedTech... read more
BioPhorum Deliverables Report
BioPhorum brings you the latest Deliverables Report, an informative and inspiring consolidation of the benchmarks, position papers, guidance documents, assessment tools, industry user requirements, study results, and roadmaps produced in the last twelve months.
BioPhorum Downloads
Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.
Case Studies
Welcome to the BioPhorum case studies page, where you can learn how our clients have used our service to discover innovative solutions and save money. Here you can read real-life stories of how various organizations have used our unique data-driven approach to streamline their processes and make the most of their resources. Whether you're looking for inspiration or want to learn more about the potential benefits of our service, you'll find it here.
Webinars and podcasts
Welcome to BioPhorum Connect, the podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, this podcast brings you the insights and perspectives of experts from around the world. We'll discuss all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. So, join us on our journey as we explore the world of biopharmaceuticals and learn from the perspectives of those at the forefront of the industry.